A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients.

Li, Pu-Yu; Li, San-Qiang; Gao, She-Gan; Dong, Dao-Yin

Li, Pu-Yu; Li, San-Qiang; Gao, She-Gan; Dong, Dao-Yin.

Afiliação

Li PY; Department of General Medicine, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, China.
Li SQ; Henan Centre for Engineering and Technology Research on Prevention and Treatment of Liver Diseases, College of Basic Medicine, Henan University of Science and Technology, Luoyang 471000, China.
Gao SG; Henan Key Laboratory of Cancer Epigenetics, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, China.
Dong DY; Department of Public Health, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang 471000, China.

Med Hypotheses ; 159: 110754, 2022 Feb.

Article em En | MEDLINE | ID: mdl-35002020

Assuntos

COVID-19; SARS-CoV-2; Sistemas CRISPR-Cas/genética; Genoma Viral; Humanos; RNA Viral

Palavras-chave

ACE2, Angiotensin-converting enzyme 2; COVID-19; COVID-19, Coronavirus disease 2019; CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; CRISPR/Cas13; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; scRNA-seq; scRNA-seq, Single-cell RNA-seq

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Med Hypotheses Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google